Pilot study of the effect of cholecalciferol supplementation on hepcidin in children with chronic kidney disease: Results of the D-fense Trial.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Hepcidin is a key mediator of the anemia of chronic kidney disease (CKD).

There is emerging evidence that 25-hydroxyvitamin D (25D) regulates hepcidin production.

Who Took Part

The age groups tagged for this paper are children, both men and women.

How the Study Was Run

The researchers set it up as a randomized and pilot study.

The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

It is described as a pilot, a small early test of whether a larger Vitamin D, K2, Magnesium and Zinc study would be practical.

Hepcidin was quantified using a validated competitive enzyme-linked immunosorbent assay. 25D levels were measured using the chemiluminescence Liaison 25(OH)D assay system.

Co-variables included hemoglobin, C-reactive protein, ferritin, and serum calcium and phosphorus for safety monitoring.

What Was Measured

Topics PubMed links to this paper include C-Reactive Protein, Cholecalciferol, Cohort Studies, Dietary Supplements, Glomerular Filtration Rate, Hepcidins and Patient Compliance.

Author keywords: Anemia, Children, Chronic kidney fisease and Vitamin D.

What This Means in Plain Language

The paper is a randomized and pilot study of Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2017 (Pediatric nephrology (Berlin, Germany)), a journal based in Germany.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.